Hopp til hovedinnhold

Kolorektalkreft

Sist oppdatert: Sist revidert:
Sist revidert av:


Definisjon:
Kreftsvulst i kolon eller rektum. Nesten 2/3 er lokalisert til rektum og sigmoideum. 98% er adenokarsinom. Skyldes både genetiske og miljømessige faktorer
Forekomst:
Livstidsinsidens er ca. 5% for menn og ca. 4% for kvinner, og den er økende
Symptomer:
Avhenger av lokalisasjon. Ofte diffuse tidlig i forløpet. Mest typisk er avføringsendringer, følelse av ufullstendig tømning, symptomer på anemi, blod i avføringen (rødt), slim i avføringen og defekasjonssmerter
Funn:
Avhenger av lokalisasjon, men sjekk oppfylninger, ev. tegn til metastaser til lymfeknuter og lever. Rektal palpasjon kan avdekke 10%
Diagnostikk:
Test på blod i avføring, Hb, leverfunksjonsprøver. Koloskopi ved mistanke om endetarmskreft. Histologi bekrefter diagnosen
Behandling:
Kirurgi ved lokalisert kreft. Ved lokalavansert kreft opereres etter preoperativ kjemoterapi/ strålebehandling. Metastaser behandles medikamentelt, ev. med stråler, i en del tilfeller kirurgisk
  • Nasjonal kompetansetjeneste for seneffekter etter kreftbehandling, nettsted 
  • Nasjonal behandlingstjeneste for hyperterm intraperitoneal kjemoterapi (HIPEC) ved kolorektal kreft, pseudomyksoma peritoneii og peritonealt mesoteliom, Oslo universitetssykehus HF, nettsted 
  • Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm. 2021.
  • Tom-Harald Edna, overlege i kirurgi Sykehuset Levanger og professor ved det medisinske fakultet, NTNU
  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm, 2019. www.helsebiblioteket.no  
  2. American Joint Committee on Cancer. AJCC Cancer Staging Manual 7. utg. New-York: Springer-Verlag, 2006: 107-17.
  3. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no  
  4. Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. 2022;386(16):1547-1558. PubMed  
  5. Aune D, Chan DSM, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-respons meta-analysis of prospective studies. BMJ 2011; 343: d6617. BMJ (DOI)  
  6. Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. JAMA 2005; 293: 172-82. PubMed  
  7. Wang L, Du M, Wang K, et al. Association of ultra-processed food consumption with colorectal cancer risk among men and women: results from three prospective US cohort studies. BMJ 2022; 378: e068921. doi:10.1136/bmj-2021-068921 DOI  
  8. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies.. JAMA 2010; 303: 1077-83. pmid: 20233826 PubMed  
  9. Deschoolmeester V, Van Marck V, Baay M, et al. Detection of HPV and the role of p16INK4A overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer. BMC Cancer 2010: 10: 117. pmid: 20346145 PubMed  
  10. Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. UpToDate, last updated Feb 17, 2021. UpToDate  
  11. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology, Nov 2015; 149: 1438-1445. pmid: 26255045 PubMed  
  12. Søreide K. Genetikk og molekylær klassifisering ved kolorektal kreft. Tidsskr Nor Lægeforen 2007; 127: 2818-23. PubMed  
  13. Compton CC. Pathology and prognostic determinants of colorectal cancer. UpToDate, last updated Feb 27, 2020. UpToDate  
  14. Henriksen M, Moum B. Kolorektal kreft ved inflammatorisk tarmsykdom. Tidsskr Nor Lægeforen 2007; 127: 2696-9. PubMed  
  15. Nieminen U, Färkkilä M. Malignancies in inflammatory bowel disease. Scand J Gastroenterol 2015; 50(1): 81-9. pmid:25523559 PubMed  
  16. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611-616. PubMed  
  17. Li X, Jansen L, Chang-Claude J, et al. Risk of Colorectal Cancer Associated With Lifetime Excess Weight. JAMA Oncol 2022. pmid:35297997 PubMed  
  18. Botteri E, Iodice S, Bagnardi V, et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300:2765. Journal of the American Medical Association  
  19. Fretheim A, Reinar LM, Brettahuer M. Helseeffekter av screening for kolorektal kreft. Rapport 2016. Oslo: Folkehelseinstituttet 2016. helsedirektoratet.no  
  20. Holme Ø, Løberg M, Kalager M, et al. Effect og flexible sigmoidoscopy screening on colorectal cancer incidence and mortality. A randomized clinical trial. JAMA 2014; 312: 696-15. doi:10.1001/jama.2014.8266 DOI  
  21. Thiis-Evensen E, Kalager M, Bretthauer M, Hoff G. Long term effectiveness of endoscopic screening on incidence and mortality of colorectal cancer: A randomized trial. UEG journal 2013; 1: 162-8. doi:10.1177/2050640613483290 DOI  
  22. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106-14. pmid:24047060 PubMed  
  23. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD009259.pub2 Cochrane (DOI)  
  24. Hoff G, Grotmol T, Skovlund E, Bretthauer M, and for the the Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009; 338: b1846. BMJ (DOI)  
  25. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, et al. Timelag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ 2012; 345: e8441. BMJ (DOI)  
  26. Tang V, Boscrdin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ 2015; 350: h1662. doi:10.1136/bmj.h1662 DOI  
  27. Juul FE, Cross AJ, Schoen RE, et al. 15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality : A Pooled Analysis of Randomized Trials. Ann Intern Med 2022. pmid:36215714 PubMed  
  28. Bretthauer M, Loberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. N Engl J Med. 2022. PMID: 36214590 PubMed  
  29. Kapidzic A, Grobbee EJ, Hol L, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014; 109: 1257-64. doi:10.1038/ajg.2014.168 DOI  
  30. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial . Lancet 2010; 375: 1624-33. PubMed  
  31. Bretthauer M, Kaminski MF, Løberg M, et al. Population-based colonoscopy screening for colorectal cancer. JAMA Intern Med 2016; 176: 894-902. doi:10.1001/jamainternmed.2016.0960 DOI  
  32. Edna TH, Karlsen V, Jullumstrø E, Lydersen S. Prevalence of anaemia at diagnosis of colorectal cancer: assessment of associated risk factors. Hepatogastroenterology 2012; 59: 713-6. PubMed  
  33. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: Systematic review and meta-analysis. Ann Intern Med 2014; 160: 171-81. doi:10.7326/M13-1484 DOI  
  34. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical Fecal Occult Blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012 Jul 31. pmid:PMID: 22850431 PubMed  
  35. Randel KR, Botteri E, Romstad KMK, et al. Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. Gastroenterology 2019. doi:10.1053/j.gastro.2019.01.040 DOI  
  36. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142: 81-85. pmid: 15657155 PubMed  
  37. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015 Dec 10;12:CD011134. Cochrane (DOI)  
  38. Konishi T, Shimada Y, Hsu M, et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology 2018; 4: 309-315. pmid: 29270608 PubMed  
  39. Jahnsen J, Røseth AG, Aadland E. Måling av kalprotektin i feces. Tidsskr Nor Legeforen 2009; 129: 743-5. Tidsskrift for Den norske legeforening  
  40. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370:1287-1297. DOI: 10.1056/NEJMoa1311194 DOI  
  41. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet 2013. doi:10.1016/S0140-6736(12)62124-2 DOI  
  42. Gao Y, Wang J, Lv H, et al. Diagnostic value of magnetic resonance and computed tomography colonography for the diagnosis of colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(39):e17187. PMID: 31574825. PubMed  
  43. Martín-López JE, Beltrán-Calvo C,Rodríguez-López R, et al. Comparison of the accuracy of CT colonography and colonoscopy in the diagnosis of colorectal cancer. Colorectal Dis. 2014;16(3):O82-9. doi: 10.1111/codi.12506 DOI  
  44. Kjellmo Å, Drolsum A. Diagnostikk og stadieinndeling av kolorektal kreft. Tidsskr Nor Lægeforen 2007; 127: 2824-8. PubMed  
  45. Bretthauer M. Kan CT-kolografi erstatte koloskopi?. Tidsskr Nor Lægeforen 2006; 126: 1464. PubMed  
  46. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321: 531-5. British Medical Journal  
  47. Sloothaak DA, Mirck B,Punt CJ, et al. Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review. Br J Cancer. 2014 ;111(6):1112-21. doi: 10.1038/bjc.2014.369. DOI  
  48. Cashin PH, Dranichnikov F, Mahteme H. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate. J Surg Oncol. 2014;110(2):203-6. doi: 10.1002/jso.23610.
  49. Balteskard L, Vonen B, Frykholm G et al. Strålebehandling av endetarmskreft Tidsskr Nor Lægeforen 2007; 127; 3090-3.
  50. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-20. PubMed  
  51. Dahl O. Adjuvant kjemoterapi ved tykktarmskreft Tidsskr Nor Lægeforen 2007; 127. 3094-6.
  52. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358: 1291-304. PubMed  
  53. Nesbakken A, Gaard M. Kirurgisk behandling av tykktarmskreft. Tidsskr Nor Lægeforen 2007; 127: 2942-5. Tidsskrift for Den norske legeforening  
  54. Kuhry E, Sætnan E, Græslie H et al. Laparoskopi ved kolorektal kreft Tidsskr Nor Lægeforen 2007; 127: 2946-9. PubMed  
  55. Røkke O, Færden AE, Øvrebø K. Transanal endoskopisk mikrokirurgi ved svulster i rectum Tidsskr Nor Lægeforen 2007; 127: 2954-8. PubMed  
  56. Rosenberg J. Laparoskopisk colonkirurgi. Ugeskr Læger 2005; 167: 2857. PubMed  
  57. Wibe A, Endreseth BH. Kirurgisk behandling av endetarmskreft. Tidsskr Nor Lægeforen 2007; 127: 2950-3. PubMed  
  58. Bülow S, Christensen IJ, Harling H, Kronborg O, et al. Lokalrecidiv og overlevelse efter total mesorektal excision for rectumcancer. Ugeskr Læger 2005; 167: 401-3. PubMed  
  59. Pfeiffer P, Baatrup G, Jensen HA, Kronborg O. Ny behandlingsstrategi for patienter med primær, ikkeresektabel rectumcancer. Ugeskr Læger 2006; 168: 1857. PubMed  
  60. Martínez-Pérez A, Carra MC, Brunetti F, de'Angelis N. Pathologic outcomes of laparoscopic vs open mesorectal excision for rectal cancer: a systematic review and meta-analysis. JAMA Surg. 2017 Feb 8:e165665 . doi:10.1001/jamasurg.2016.5665 DOI  
  61. Andersen HK, et al. Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev, issue 4, 2006. The Cochrane Library  
  62. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16(13): 1306-15. pmid:26338525 PubMed  
  63. Søreide JA, Eiriksson K, Sandvik O et al. Kirurgisk behandling av levermetastaser fra kolorektal kreft. Tidsskr Nor Legeforen 2008; 128: 50-3. Tidsskrift for Den norske legeforening  
  64. Frich L. Lokal ablasjon av kolorektale levermetasaser - en systematisk oversikt. Tidsskr Nor Legeforen 2008; 128: 54-6. Tidsskrift for Den norske legeforening  
  65. Frich L, Brabrand K, Aaløkken TM et al. Radiofrekvensablasjon av kolorektale levermetastaser. Tidsskr Nor Legeforen 2008; 128: 57-60. Tidsskrift for Den norske legeforening  
  66. Fong Y, Gonen M, Rubin D et al. Long-term survival is superior after resection for cancer in high-volum centers. Ann Surg 2005; 242: 540-4. PubMed  
  67. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 24: 4954-5. PubMed  
  68. Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol 2012; 47: 296-314. PubMed  
  69. Edna TH, Jullumströ E, Lydersen S. Chemotherapy for nonresectable colorectal cancer at a center during 25 years. Hepatogastroenterology 2008; 55: 2049-53. PubMed  
  70. Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol. 2016 Apr;100:117-26. Epub 2016 Jan 23. PMID:26850575 PubMed  
  71. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011; 29: 3761. PubMed  
  72. Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021 Jul;22(7):1002-1013. Epub 2021 May 25. PMID: 34048685. PubMed  
  73. Van Blarigan EL, Fuchs CS, Niedzwiecki D et al. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis The CALGB 89803/Alliance Trial. JAMA Oncol 2018; 4: 783-790. pmid:29710284 PubMed  
  74. Yang B, Jacobs EJ, Gapstur SM, et al. Active Smoking and Mortality Among Colorectal Cancer Survivors: The Cancer Prevention Study II Nutrition Cohort. J Clin Oncol 2015; 33: 885-93. doi:10.1200/JCO.2014.58.3831 DOI  
  75. Yao Y, Suo T, Andersson R, et al. Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD003430. DOI: 10.1002/14651858.CD003430.pub2. DOI  
  76. Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment Pharmacol Ther 2006; 24: 281-91. PubMed  
  77. Bretthauer M, Hoff G. Forebygging og tidlig diagnostikk av kolorektal kreft. Tidsskr Nor Lægeforen 2007; 127: 2688-91. PubMed  
  78. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005: 294: 914-23.
  79. Friis S, Riis AH, Erichsen R, et al. Low-dose aspirin and nonsteroidal anti-inflammatory drug use and colorectal cancer risk: A population-based, case-control study. Ann Intern Med 2015. doi:10.7326/M15-0039 DOI  
  80. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2007; 146: 361-4. Annals of Internal Medicine  
  81. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376-89. Annals of Internal Medicine  
  82. Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50. PubMed  
  83. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the u.s. Preventive services task force. Ann Intern Med 2007; 146: 365-75. Annals of Internal Medicine  
  84. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13. PubMed  
  85. Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-7. PubMed  
  86. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term eff ects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefi ts in 51 randomised controlled trials. Lancet 2012; : DOI:10.1016/S0140-. DOI  
  87. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601. PubMed  
  88. National Cancer Institute. Can Taking Aspirin Help Prevent Cancer? Last updated August 2020. www.cancer.gov  
  89. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418-23. PubMed  
  90. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92. New England Journal of Medicine  
  91. Chan MK, Law WL. Use of chewing gum in reducing postoperative ileus after elective colorectal surgery. A systematic review. Dis Colon Rectum 2007: 50: 2149-57.
  92. Gögenur I, Wittendorff H-E, Colstrup H, Rosenberg J, Fischer A. Følger efter behandling af kolorektal cancer med særlig fokus på stomiproblemer, urologiske følgetilstande og seksuel dysfunktion. Ugeskr Læger 2005; 167: 4272-5. PubMed  
  93. Robertson I, Leung E, Hughes D et al. Prospective analysis of stoma-related complications. Colorectal Dis 2005; 7: 279-85. PubMed  
  94. Petrelli F, Tomasello G, Borgonovo K et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon CancerA Systematic Review and Meta-analysis. JAMA Oncol. Published online October 27, 2016. pmid:27787550 PubMed  
  95. Løberg M, Kalager M, Holme Ø, et al. Long-Term Colorectal-Cancer Mortality after Adenoma Removal. N Engl J Med 2014; 371: 799-807. doi:10.1056/NEJMoa1315870 DOI  
  • Terje Johannessen, professor i allmennmedisin, Trondheim